Bladder Cancer Clinical Trial
Evaluation of the PhageTech Virus BioResistor
Summary
To evaluate the effectiveness of the PhageTech Virus BioResistor to detect bladder cancer biomarkers.
Full Description
This study will sample urine provided by bladder cancer patients as part of their normal routine surveillance screening. No additional effort will be required from the patients and only modest additional effort from the study staff. Some de-identified patient medical information may also be requested, including concominant medications, relevant current or previous diseases, prior bladder cancer interventions and other relevant information to ensure there are no interfering substances or other confounders that could affect study results. There is no risk to patients as the normal diagnostics for bladder cancer will be followed.
Eligibility Criteria
Inclusion Criteria:
Male and female patients ≥ 18 years
Previous bladder cancer diagnosis; any stage and histological type, undergoing cystoscopy
Patients with suspected bladder tumor undergoing surveillance cystoscopy
Patients must provide written Informed Consent.
Exclusion Criteria:
Patients unable or unwilling to sign the informed consent
Age < 18 years
Known HIV/HCV/HBV (information from clinical history).
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Santa Monica California, 90404, United States More Info
How clear is this clinincal trial information?